换肤

申联生物

i问董秘

A03355

主营介绍

  • 主营业务：

    专业从事兽用生物制品研发、生产、销售及服务

  • 产品类型：

    口蹄疫疫苗

  • 产品名称：

    猪口蹄疫O型合成肽疫苗 、 猪口蹄疫O型 、 A型二价合成肽疫苗

  • 经营范围：

    采用生物工程技术研究开发及生产生物制品、人工合成肽等药用原料，销售自产产品；从事生物制品、人工合成肽等药用原料（不含危险化学品和药品）的批发，并提供相关的技术服务（以上除人体干细胞、基因诊断与治疗技术的开发和应用）。自有房屋租赁。【依法须经批准的项目，经相关部门批准后方可开展经营活动】

主营构成分析

报告期
报告期
{"2019-06-30":{"YYSR":{"2":[["\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","8022.65"],["\u732a\u53e3\u8e44\u6021O\u578b\u3001A\u578b\u4e8c\u4ef7\u5408\u6210\u80bd\u75ab\u82d7","5015.73"]],"3":[["\u4e2d\u539f\u533a","3955.09"],["\u534e\u4e1c\u533a","2644.54"],["\u897f\u5357\u533a","2183.30"],["\u4e1c\u5317\u533a","2093.26"],["\u534e\u5357\u533a","1343.35"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",818.83]]},"YYCB":{"2":[["\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7",""],["\u732a\u53e3\u8e44\u6021O\u578b\u3001A\u578b\u4e8c\u4ef7\u5408\u6210\u80bd\u75ab\u82d7",""]],"3":[["\u4e2d\u539f\u533a",""],["\u534e\u4e1c\u533a",""],["\u897f\u5357\u533a",""],["\u4e1c\u5317\u533a",""],["\u534e\u5357\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]},"LRBL":{"2":[["\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7",""],["\u732a\u53e3\u8e44\u6021O\u578b\u3001A\u578b\u4e8c\u4ef7\u5408\u6210\u80bd\u75ab\u82d7",""]],"3":[["\u4e2d\u539f\u533a",""],["\u534e\u4e1c\u533a",""],["\u897f\u5357\u533a",""],["\u4e1c\u5317\u533a",""],["\u534e\u5357\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]}},"2018-12-31":{"YYSR":{"2":[["\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","27506.36"]],"3":[["\u4e2d\u539f\u533a","8709.12"],["\u534e\u4e1c\u533a","6723.38"],["\u897f\u5357\u533a","6554.05"],["\u4e1c\u5317\u533a","2088.88"],["\u534e\u5357\u533a","1993.04"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1437.9]]},"YYCB":{"2":[["\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","5456.78"]],"3":[["\u4e2d\u539f\u533a",""],["\u534e\u4e1c\u533a",""],["\u897f\u5357\u533a",""],["\u4e1c\u5317\u533a",""],["\u534e\u5357\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]},"LRBL":{"2":[["\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","100.00"]],"3":[["\u4e2d\u539f\u533a",""],["\u534e\u4e1c\u533a",""],["\u897f\u5357\u533a",""],["\u4e1c\u5317\u533a",""],["\u534e\u5357\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]}},"2017-12-31":{"YYSR":{"2":[["\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","30194.13"]],"3":[["\u4e2d\u539f\u533a","10174.08"],["\u534e\u4e1c\u533a","7437.65"],["\u897f\u5357\u533a","5636.51"],["\u4e1c\u5317\u533a","3494.88"],["\u534e\u5357\u533a","2375.71"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1075.3]]},"YYCB":{"2":[["\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","6050.64"]],"3":[["\u4e2d\u539f\u533a",""],["\u534e\u4e1c\u533a",""],["\u897f\u5357\u533a",""],["\u4e1c\u5317\u533a",""],["\u534e\u5357\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]},"LRBL":{"2":[["\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","100.00"]],"3":[["\u4e2d\u539f\u533a",""],["\u534e\u4e1c\u533a",""],["\u897f\u5357\u533a",""],["\u4e1c\u5317\u533a",""],["\u534e\u5357\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]}}}
{"YYSR":{"chartWrap2":[{"name":"\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[8022.65,27506.36,30194.13],"columnData":[61.53,100,100],"unit":["8022.65\u4e07","2.75\u4ebf","3.02\u4ebf"]},{"name":"\u732a\u53e3\u8e44\u6021O\u578b\u3001A\u578b\u4e8c\u4ef7\u5408\u6210\u80bd\u75ab\u82d7","timeData":["2019-06-30"],"lineData":[5015.73],"columnData":[38.47],"unit":["5015.73\u4e07"]}],"chartWrap3":[{"name":"\u4e2d\u539f\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[3955.09,8709.12,10174.08],"columnData":[30.33,31.66,33.7],"unit":["3955.09\u4e07","8709.12\u4e07","1.02\u4ebf"]},{"name":"\u534e\u4e1c\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[2644.54,6723.38,7437.65],"columnData":[20.28,24.44,24.63],"unit":["2644.54\u4e07","6723.38\u4e07","7437.65\u4e07"]},{"name":"\u897f\u5357\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[2183.3,6554.05,5636.51],"columnData":[16.75,23.83,18.67],"unit":["2183.30\u4e07","6554.05\u4e07","5636.51\u4e07"]},{"name":"\u4e1c\u5317\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[2093.26,2088.88,3494.88],"columnData":[16.05,7.59,11.57],"unit":["2093.26\u4e07","2088.88\u4e07","3494.88\u4e07"]},{"name":"\u534e\u5357\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[1343.35,1993.04,2375.71],"columnData":[10.3,7.25,7.87],"unit":["1343.35\u4e07","1993.04\u4e07","2375.71\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[818.83,1437.9,1075.3],"columnData":[6.28,5.23,3.56],"unit":["818.83\u4e07","1437.90\u4e07","1075.30\u4e07"]}]},"YYCB":{"chartWrap2":[{"name":"\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,5456.78,6050.64],"columnData":[0,100,100],"unit":["0.00","5456.78\u4e07","6050.64\u4e07"]},{"name":"\u732a\u53e3\u8e44\u6021O\u578b\u3001A\u578b\u4e8c\u4ef7\u5408\u6210\u80bd\u75ab\u82d7","timeData":["2019-06-30"],"lineData":[0],"columnData":[0],"unit":["0.00"]}],"chartWrap3":[{"name":"\u4e2d\u539f\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u4e1c\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u897f\u5357\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u4e1c\u5317\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5357\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]}]},"LRBL":{"chartWrap2":[{"name":"\u732a\u53e3\u8e44\u6021O\u578b\u5408\u6210\u80bd\u75ab\u82d7","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,100,100],"columnData":[0,100,100],"unit":["0.00","100.00\u4e07","100.00\u4e07"]},{"name":"\u732a\u53e3\u8e44\u6021O\u578b\u3001A\u578b\u4e8c\u4ef7\u5408\u6210\u80bd\u75ab\u82d7","timeData":["2019-06-30"],"lineData":[0],"columnData":[0],"unit":["0.00"]}],"chartWrap3":[{"name":"\u4e2d\u539f\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u4e1c\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u897f\u5357\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u4e1c\u5317\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5357\u533a","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]}]}}

营业收入 X

单位（%） 单位（万元）
注：通常在中报、年报时披露　
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按产品 猪口蹄怡O型合成肽疫苗 8022.65万 61.53% - - - -
猪口蹄怡O型、A型二价合成肽疫苗 5015.73万 38.47% - - - -
按地区 中原区 3955.09万 30.33% - - - -
华东区 2644.54万 20.28% - - - -
西南区 2183.30万 16.75% - - - -
东北区 2093.26万 16.05% - - - -
华南区 1343.35万 10.30% - - - -
其他区 818.83万 6.28% - - - -

董事会经营评述

　　1、营业收入变动情况.
　　公司是一家专业从事兽用生物制品研发、生产、销售的高新技术企业，主要产品为猪口蹄疫疫苗，主营业务突出。报告期内，公司主营业务收入分别为26,770.54万元、30,194.13万元和27,506.36万元。
　　（1）主营业务收入的变动原因分析.
　　2017年，公司主营业务收入较2016年增长3,423.59万元，增幅为12.79%。
　　主要原因为：①我国养殖业的规模化水平逐渐提高，政府对动物疫病的重视程度提升，兽用疫苗市场规模扩大；②公司产品品质稳定，市场认可度高，在猪口蹄疫合成肽疫苗领域的市场占有率超过50%，以及公司加强了市场开拓力度。
　　2018年，... 查看全部▼

　　1、营业收入变动情况.
　　公司是一家专业从事兽用生物制品研发、生产、销售的高新技术企业，主要产品为猪口蹄疫疫苗，主营业务突出。报告期内，公司主营业务收入分别为26,770.54万元、30,194.13万元和27,506.36万元。
　　（1）主营业务收入的变动原因分析.
　　2017年，公司主营业务收入较2016年增长3,423.59万元，增幅为12.79%。
　　主要原因为：①我国养殖业的规模化水平逐渐提高，政府对动物疫病的重视程度提升，兽用疫苗市场规模扩大；②公司产品品质稳定，市场认可度高，在猪口蹄疫合成肽疫苗领域的市场占有率超过50%，以及公司加强了市场开拓力度。
　　2018年，公司主营业务收入较2017年下降2,687.77万元，降幅为8.90%。
　　主要原因为：①公司2018年在黑龙江省未中标，导致公司当年在黑龙江省销售额下降；②河南省于2018年下半年开始采购O型、A型二价疫苗，而公司O型、A型二价合成肽疫苗产品批准文号于2018年12月取得，导致公司当年在河南省的销售额下降1,603.21万元。随着公司新产品O型、A型二价合成肽疫苗的推出，将有利于提升公司的市场竞争力，促进公司业务增长。
　　（2）主营业务收入的量价分析.
　　2017年，公司销售收入增长12.79%，主要系2017年公司平均销售价格与销售数量均上升，其中销售价格较2016年上升9.20%，销售数量较2016年上升3.57%。2018年，公司销售收入下降8.90%，主要系2018年公司平均销售价格较2017年增长2.11%，但销售数量下降了11.12%。
　　2、主营业务收入分销售模式分析.
　　猪口蹄疫具有急性、热性、高度接触性的特点，为我国一类动物传染病，国家对口蹄疫实行强制免疫政策，各地动物防疫主管部门通过招投标方式对口蹄疫疫苗进行采购。报告期内，公司主要通过招投标方式向政府部门进行销售口蹄疫疫苗，政府采购占比分别为98.71%、94.62%和94.80%。公司亦向猪场进行直接销售，直接销售占比分别为1.29%、5.38%和5.20%。
　　报告期内，公司通过政府采购实现的销售收入分别为26,424.14万元、28,568.49万元和26,077.18万元。公司针对我国猪口蹄疫疫情流行趋势不断对产品进行研发升级，疫苗产品效力较好，质量稳定，在全国范围内享有较高的知名度。公司已先后在全国30个省、市、自治区中标，公司现有产品猪口蹄疫O型合成肽疫苗受到各地动物疫病主管部门的广泛认可。
　　报告期内，公司直接销售金额分别346.41万元、1,625.64万元和1,429.18万元，2017年及2018年公司直接销售金额相比2016年度增长较快。公司组建了专业化的市场化销售队伍。2016年以来，公司积极在市场化销售产品、销售队伍、销售网络、销售制度等作出准备，已开拓了上百家猪场客户。
　　3、主营业务收入分区域分析.
　　公司产品销售地域广泛，收入集中度较低。公司产品在中原、华东和西南区域实现销售较多，与我国主要畜牧养殖区域分布一致。报告期内公司在这三个区域的产品销售占比超过70%。
　　4、主营业务收入的季节性分析.
　　公司疫苗收入主要集中于春秋两季，根据国家动物强制免疫计划，春秋两季需对所有易感家畜进行一次集中免疫，简称为“春防”、“秋防”。相应地，地方政府相关部门对强制免疫用生物制品进行春秋两季招标，公司产品销售亦集中在上述时间段。报告期，公司第一季度、第三季度收入合计占当年主营业务收入的70%以上。 收起▲

同花顺个股页面 | F10论坛 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。